Prelude Capital Management, LLC Protagonist Therapeutics, Inc Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$5.4 - $9.22 $8,640 - $14,752	-1,600 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $7,504 - $21,520	1,600 New	1,600 $11,000
Q4 2018 Feb 14, 2019	SELL	$6.3 - $10.44 $4,302 - $7,130	-683 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $30,805 - $50,861	-4,517 Reduced 86.87%	683 $7,000
Q2 2018 Aug 14, 2018	SELL	$5.99 - $9.1 $17,371 - $26,390	-2,900 Reduced 35.8%	5,200 $35,000
Q1 2018 May 15, 2018	BUY	$8.46 - $23.08 $68,526 - $186,948	8,100 New	8,100 $70,000

195

58.7M

20.8K

109K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.